🔗 Share this article

As America continues making unprecedented adjustments to its vaccine schedules, a particular individual has emerged somewhat surprisingly: Høeg, an American of Danish descent sports medicine doctor and public health researcher who rose to prominence by questioning COVID-19 vaccinations throughout the pandemic and has concentrated on possible fatalities after COVID-19 vaccination in her short time at the Food and Drug Administration.

Proposed Changes to Childhood Vaccine Schedule

Health officials had intended to announce sweeping changes to the pediatric immunization program earlier this month, aligning the US with the Danish national calendar, it is understood – a significant shift that would put the US out of alignment with many the global community with insufficient data for public health gain. The planned update has been pushed back until the next year.

In place of the director of the vaccine center, Dr. Høeg is listed to speak at the meeting. She was just designated interim head of the FDA’s CDER, the fifth person to lead the office this year.

A Shift at the Regulatory Body

This interim role could signify a tighter collaboration between the drug and vaccine centers as Dr. Høeg and Prasad solidify control at the FDA – and it signals a renewed priority upon reevaluating long-standing immunizations at the FDA.

Høeg has repeatedly called for discontinuing certain pediatric vaccine recommendations in the US in order to be more similar to the Danish model, a society with nationalized medicine and a number of inhabitants roughly the size of the state of Wisconsin.

In her initial comments, she has continued to focus on vaccines – typically the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Questions Over Expertise

The appointee has no obvious track record in medication creation, approval processes or administrative roles, which has been standard for past directors of the CBER. She has served at the FDA as a key advisor to the commissioner and CBER since March.

“She doesn’t seem to have the requisite experience” for overseeing the CDER, stated a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She has no expertise in managing a major agency. She lacks background in drug approvals.”

Previous heads of CBER would “grasp laws and regulations and the research of medication creation”, noted Dr. Janet Woodcock. “Frankly, she doesn’t have the type of experience that prior appointees who headed CBER have had.”

This division has an immense range of responsibilities at the agency, Woodcock stated.

“Many people just focuses on the new drug program, but the generic program approves numerous off-brand pharmaceuticals. There is also a biosimilars division, OTC medication office and other areas, and all of those need to be supervised,” Dr. Woodcock noted. “The responsibility you overlook, that’s the thing that I always told people is going to bite you.”

There is also, a substantial administrative aspect to the job, which manages more than 5,000 personnel. “It is a huge management job, if you do it right,” the former official added.

Official Statement and Controversial Initiatives

In response to inquiries about Dr. Høeg's credentials and whether this selection represents greater collaboration among FDA leaders on immunizations, a press secretary responded that the “inquiries are based on flawed premises”.

“Her experience is consistent with the responsibilities of her job,” the spokesperson stated, citing the period Høeg spent counseling the agency head on “medication safety and regulatory science, including computational safety modeling and vaccine surveillance”.

In her interim role, Høeg takes over the agency head's recently launched fast-track approval initiative, a contentious one-day therapy clearance system that reportedly worried her preceding directors. “By what process are these therapies being selected for this fast-track system? Who takes the calls?” Dr. Howard questioned. “There’s a lot of lack of transparency occurring at the FDA right now.”

In general, he stated, “the agency appears to be shifting towards laxer oversight of most medications, aside from shots.”

Documented Past Work on Immunizations

With vaccines, Dr. Høeg has a more established, if problematic, track record, some experts have noted. She released a analysis using unverified volunteer-provided data to determine the incidence of heart inflammation after COVID-19 vaccination. She advised the state of Florida chief medical officer Joseph Ladapo, who reportedly have changed statistics to suggest COVID-19 vaccines are more dangerous than they are.

Among her “policy goals” for the new federal leadership included altering regulations for novel immunizations and discontinuing “optional” vaccines, she said after the election on a audio program. At the FDA, Høeg has allegedly floated the idea of excluding young men from obtaining Covid vaccines.

“She’s an complete dogmatist who begins with her conclusions and works backwards to fit the science in a very misleading, dishonest manner,” Dr. Howard said.

Gaining Influence and a “Revenge Tour”

Høeg aligned with other skeptics, {like|